Better Contraceptive Choices: Immediate or Delayed Insertion of IUC After Second Trimester Abortion
Launched by UNIVERSITY OF BRITISH COLUMBIA · Apr 6, 2009
Trial Information
Current as of May 04, 2025
Unknown status
Keywords
ClinConnect Summary
This Randomized Controlled Trial will be offered to women choosing to have a LNG-IUC or CuT380 after an abortion for gestational ages from 12 to 24 weeks. \[delete next insert\]"and a non intervention control group offered to all others having abortions at this gestational age". Participants choosing an LNG-IUC or CUT380 will be randomly assigned to immediate or interval insertion. In conjunction with follow up visits and questionnaires, the British Columbia Linked Health Database access will determine pregnancy rate within one year for the two intervention groups \[delete next insert\] and...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Have completed informed consent for an abortion at gestation between 12 weeks zero days and 23 weeks 6 days, and
- • 2. Choosing an IUC (either LNG-IUC or CuT380-IUC) for contraception post abortion, and
- • 3. Residents of British Columbia, registered with the Medical Services Plan health care system.
- Exclusion Criteria:
- • 1. Intention to move from BC within the next year
- • 2. Intention to conceive within the next year.
- • 3. Any of the following contraindications to use of a LNG-IUC or a CuT380-IUC
- 4. Post Randomization Exclusion:
- • uterine perforation at the time of abortion
- • bleeding of more than 500 cc during abortion
- • any of the above exclusions detected at time of abortion
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Kelowna, British Columbia, Canada
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Wendy V. Norman, Ph.D
Principal Investigator
University of British Columbia
Brian Fitzsimmons, MD
Study Director
University of British Columbia
Lyda Dicus
Study Chair
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials